Brain tumor

CHILDREN’S NATIONAL HOSPITAL RECEIVES $96 MILLION INVESTMENT FOR RARE PEDIATRIC BRAIN TUMOR RESEARCH & CARE

Retrieved on: 
Wednesday, June 21, 2023
Brain, Partnership, Research, Neuroscience nursing, Children's National Hospital, Brain tumor, Hospital, Risk, Child, Medicine, Cancer, Diagnosis, Mental health, Disease, Pharmaceutical industry, Medical imaging

WASHINGTON, D.C., June 21, 2023 (GLOBE NEWSWIRE) -- Children’s National Hospital announced a $96 million investment from an anonymous donor family that strengthens its globally recognized leadership to transform rare childhood brain tumor research and care.

Key Points: 
  • WASHINGTON, D.C., June 21, 2023 (GLOBE NEWSWIRE) -- Children’s National Hospital announced a $96 million investment from an anonymous donor family that strengthens its globally recognized leadership to transform rare childhood brain tumor research and care.
  • It allows Children’s National to recruit more top talent and advance the most promising research for safer, more effective treatments.
  • The investment will elevate standards of care to help children with rare brain tumors thrive for a lifetime.
  • “It will immediately propel our best-in-class research and care, allowing us to bring new therapies to children with brain tumors.

Brain Cancer Canada Awards St. Michael’s Hospital $100,000 Grant for Advanced DNA Sequencer Technology

Retrieved on: 
Wednesday, May 31, 2023
Canada, DNA, Unity Health Toronto, Partnership, Cancer, Research, Brain, Brain tumor, Acquisition, Patient, Hospital, BCC, Medical imaging

TORONTO, May 31, 2023 (GLOBE NEWSWIRE) -- Brain Cancer Canada, the country’s leading charitable organization dedicated to brain cancer research, has announced a $100,000 grant to St. Michael’s Hospital, a site of Unity Health Toronto.

Key Points: 
  • TORONTO, May 31, 2023 (GLOBE NEWSWIRE) -- Brain Cancer Canada, the country’s leading charitable organization dedicated to brain cancer research, has announced a $100,000 grant to St. Michael’s Hospital, a site of Unity Health Toronto.
  • The funds will facilitate the acquisition of a top-of-the-line, next-generation DNA sequencer, technology that will allow St. Michael’s to develop and test innovative new treatment protocols for the toughest forms of brain cancer.
  • “It will empower us to customize treatments to individual patients, which is a major step towards improved patient outcomes.”
    For Brain Cancer Canada, this gift to St. Michael’s brain cancer program is a central element of a push to increase treatment options for brain cancer patients.
  • “Our goal at BCC is to bring more effective new treatments to patients,” said Angela Scalisi, Chair of Brain Cancer Canada.

Brain Cancer Canada Grants Research Funds to Improve Survival Rates for Glioblastoma and Other Gliomas

Retrieved on: 
Thursday, May 25, 2023
Sunnybrook, Canada, Glioblastoma, Prognosis, Research, Brain, Brain tumor, Patient, Neuro, Partnership, Sunnybrook Health Sciences Centre, Medical imaging

TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- Brain Cancer Canada, a leading charity in the fight against brain cancer, is delighted to announce a $50,000 research grant to Dr. Amit Singnurkar at Sunnybrook Health Sciences Centre.

Key Points: 
  • TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- Brain Cancer Canada, a leading charity in the fight against brain cancer, is delighted to announce a $50,000 research grant to Dr. Amit Singnurkar at Sunnybrook Health Sciences Centre.
  • The grant will support a ground-breaking study to improve the treatment of high-grade gliomas, the most aggressive form of brain cancer.
  • “We are hopeful that this research will make a significant difference in the treatment of high-grade gliomas,” Dr. Singnurkar said.
  • “This research has the potential to be a game-changer in the treatment of high-grade gliomas, such as glioblastoma,” she said.

Brain Cancer Canada Awards CAD 50,000 Grant for Innovative Research to Improve Brain Cancer Diagnosis and Treatment

Retrieved on: 
Thursday, May 4, 2023
Canada, Glioblastoma, London Health Sciences Centre, Cancer, DRS, Research, Brain, Brain tumor, Patient, Hospital, Diagnosis, Children's Hospital at London Health Sciences Centre, Caregiver, Medical imaging

TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- Brain Cancer Canada is pleased to announce a $50,000 grant to support research on more effective diagnosis and treatment for adult brain cancer patients.

Key Points: 
  • TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- Brain Cancer Canada is pleased to announce a $50,000 grant to support research on more effective diagnosis and treatment for adult brain cancer patients.
  • For Brain Cancer Canada, a leading charity supporting brain cancer research and patient advocacy, this research project is an opportunity to make a tangible difference in the lives of patients.
  • “We are thrilled to support this groundbreaking research project,” said Angela Scalisi, Chair of Brain Cancer Canada.
  • Brain Cancer Canada board director Marc Peeters highlighted the need for innovation in fighting brain cancer.

Brain Cancer Foundation CEO Announces First-Ever South Pole Trek in the Name of Cancer Research

Retrieved on: 
Wednesday, February 15, 2023
Life, Health, Human, NFCR, Organic, Brain, AFCR, Patient, Glioblastoma, Research, National Foundation for Cancer Research, Female, Survival, Disease, Brain tumor, Quality of life, Cancer, Mobile phone, Medical imaging, Pharmaceutical industry, Nursing

Cure Brain Cancer Foundation CEO Lance Kawaguchi is pledging to make the arduous trek to the South Pole to raise awareness and funding for brain cancer research.

Key Points: 
  • Cure Brain Cancer Foundation CEO Lance Kawaguchi is pledging to make the arduous trek to the South Pole to raise awareness and funding for brain cancer research.
  • Thus, the Cure Brain Cancer Foundation CEO has announced he will be making the harrowing trek to the South Pole in order to raise awareness and funds for cancer research.
  • Kawaguchi and Cure Brain Cancer Foundation are calling on more charities, not-for-profits and investors to come together to raise critical funds for cancer research, with brain cancer being one of the most underfunded forms of cancer.
  • Cure Brain Cancer Foundation: Cure Brain Cancer Foundation is an Australian-based organization working globally to rapidly improve brain cancer survival.

Brain Cancer Foundation CEO Announces First-Ever South Pole Trek in the Name of Cancer Research

Retrieved on: 
Tuesday, February 14, 2023
Life, Health, Human, NFCR, Organic, Brain, AFCR, Patient, Glioblastoma, Research, National Foundation for Cancer Research, Female, Survival, Disease, Brain tumor, Quality of life, Cancer, Mobile phone, Medical imaging, Pharmaceutical industry, Nursing

Cure Brain Cancer Foundation CEO Lance Kawaguchi is pledging to make the arduous trek to the South Pole to raise awareness and funding for brain cancer research.

Key Points: 
  • Cure Brain Cancer Foundation CEO Lance Kawaguchi is pledging to make the arduous trek to the South Pole to raise awareness and funding for brain cancer research.
  • Thus, the Cure Brain Cancer Foundation CEO has announced he will be making the harrowing trek to the South Pole in order to raise awareness and funds for cancer research.
  • Kawaguchi and Cure Brain Cancer Foundation are calling on more charities, not-for-profits and investors to come together to raise critical funds for cancer research, with brain cancer being one of the most underfunded forms of cancer.
  • Cure Brain Cancer Foundation: Cure Brain Cancer Foundation is an Australian-based organization working globally to rapidly improve brain cancer survival.

Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors

Retrieved on: 
Monday, January 9, 2023
Vice, Disease, Brain, Neuro, ST, Teaching hospital, University, Neoplasm, Brain tumor, Safety, Pathology, NYSE, Toxic leukoencephalopathy, Therapy, Patient, Cancer, Clinical trial, Medical imaging

ROCKVILLE, Md., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the first patient has been dosed in the Phase 1 investigator sponsored clinical trial of VCN-01, an intravenous oncolytic adenovirus, for patients with high-grade brain tumors who are scheduled for surgical resection.

Key Points: 
  • “We are pleased to dose the first patient and evaluate the ability of our lead oncolytic adenovirus, VCN-01, to enter brain tumors following systemic administration,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
  • “This design builds on the data that we obtained from previous trials of systemically delivered VCN-01 for treating metastatic pancreatic cancer, another difficult to treat disease.
  • Dr. Samson commented, “Patients with recurrent high-grade primary brain tumors typically have a poor prognosis, and often have to undergo one or more surgical interventions to remove their tumors.
  • This could provide a more effective and less invasive therapeutic option for these patients.”

US FDA Grants Breakthrough Designation for Blood Test to Help Diagnose Inaccessible Brain Tumors

Retrieved on: 
Monday, January 2, 2023
Surgeon, US Food Sovereignty Alliance, Patient, CE, Neoplasm, Cell, Brain, Food, Liquid biopsy, Disease, Chinese, Diagnosis, Breast, Blood, Imperial College London, FDA, NABL, Certification, Genetics, Device, Breakthrough, CTC, USFDA, CAP, Principal, Imperial College Healthcare NHS Trust, Brain tumor, ISO, CLIA, Cancer, GCC, Medical imaging, Medical device

LONDON , Jan. 2, 2023 /PRNewswire/ -- Datar Cancer Genetics Inc announced today that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its 'TriNetra™-Glio', a blood test to help in the diagnosis of brain tumors. This is the third test from the Company to have received the Breakthrough Device Designation from the US FDA. The Company's early-stage breast and prostate cancer detection tests became the first liquid biopsies to receive the Breakthrough Device Designation.

Key Points: 
  • LONDON , Jan. 2, 2023 /PRNewswire/ -- Datar Cancer Genetics Inc announced today that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its 'TriNetra™-Glio', a blood test to help in the diagnosis of brain tumors.
  • This is the third test from the Company to have received the Breakthrough Device Designation from the US FDA.
  • The Company's early-stage breast and prostate cancer detection tests became the first liquid biopsies to receive the Breakthrough Device Designation.
  • Diagnosis of brain tumors is resource-intensive, risk-prone and brain biopsies are impossible to perform in almost 40% of advanced cases.

US FDA Grants Breakthrough Designation for Blood Test to Help Diagnose Inaccessible Brain Tumors

Retrieved on: 
Monday, January 2, 2023
Surgeon, US Foods, Patient, CE, Neoplasm, Cell, Brain, Food, US, Liquid biopsy, Disease, Chinese, Diagnosis, Breast, Blood, Imperial College London, FDA, Certification, Genetics, Device, Breakthrough, CTC, LDT, USFDA, Principal, Laboratory developed test, Imperial College Healthcare NHS Trust, Brain tumor, Research, Cancer, GCC, Medical imaging, Medical device, DATAR, Guildford

RALEIGH, N.C., Jan. 2, 2023 /PRNewswire/ -- Datar Cancer Genetics Inc announced today that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its 'TriNetra™-Glio', a blood test to help in the diagnosis of brain tumors. This is the third test from the Company to have received the Breakthrough Device Designation from the US FDA. The Company's early-stage breast and prostate cancer detection tests became the first liquid biopsies to receive the Breakthrough Device Designation.

Key Points: 
  • RALEIGH, N.C., Jan. 2, 2023 /PRNewswire/ -- Datar Cancer Genetics Inc announced today that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its 'TriNetra™-Glio', a blood test to help in the diagnosis of brain tumors.
  • This is the third test from the Company to have received the Breakthrough Device Designation from the US FDA.
  • The Company's early-stage breast and prostate cancer detection tests became the first liquid biopsies to receive the Breakthrough Device Designation.
  • Diagnosis of brain tumors is risk-prone and brain biopsies are impossible to perform in almost 40% of advanced cases.

VETERINARY LEADERS TO SHARE BREAKTHROUGHS ACROSS THE BOARD FOR MORE EFFECTIVE CANCER TREATMENT, NON-INVASIVE DIAGNOSTICS, UNDERSTANDING FELINE PAIN AND SURGERY ON THE SMALLEST PATIENTS

Retrieved on: 
Tuesday, December 20, 2022
Sentinel, Veterinarian, HDI, Textbook, HT, Health, Cat, VMX, COVID-19, Animal, News, Loyal, Epidemiology, Analgesic, Research, Sentinel (comics), Artery, Brain tumor, Patient, Weakness, MRI, Dog, Survival rate, Pandemic, Horse, Subcutaneous tissue, Risk, Bird, Veterinary medicine, Orlando Sentinel, Cancer, Hamster, Skin, Cardiology, Human, Breast cancer, Zoonosis, Family, History, Virus, American Veterinary Medical Association, Brain, Heart, Diagnosis, Life, Multimedia, Rabbit, Ageing, The Marine Mammal Center, Anesthesia, PETS, Degenerative disease, Huber loss, Trauma, Neoplasm, Vein, CT, Seizure, Orange County Convention Center, Sea, Publication, Science, Medical imaging, Dentistry, Pain

ORLANDO, Fla., Dec. 20, 2022 /PRNewswire/ -- From breast cancer surgery on a tiny hedgehog to advanced non-invasive ways to detect cancer, perform heart surgery and measure pain, the veterinary industry continues to provide new, less painful and more successful options to help animals live longer, better quality lives. This comes as good news to pet owners who see and treat their pets as family and increasingly seek the best healthcare possible for them.

Key Points: 
  • Key topics and presenters available for interviews include:
    Note: See the VMX 2023 Full Program for session dates and times.
  • Her session will focus on how the human and veterinary medical communities work together to minimize future outbreaks.
  • The North American Veterinary Community (NAVC) is a nonprofit organization dedicated to supporting and advancing veterinary professionals worldwide.
  • Since 2017, the NAVC has been recognized as one of the Top Workplaces by the Orlando Sentinel.